Your browser doesn't support javascript.
loading
Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study.
Stepien, Magdalena; Keski-Rahkonen, Pekka; Kiss, Agneta; Robinot, Nivonirina; Duarte-Salles, Talita; Murphy, Neil; Perlemuter, Gabriel; Viallon, Vivian; Tjønneland, Anne; Rostgaard-Hansen, Agnetha Linn; Dahm, Christina C; Overvad, Kim; Boutron-Ruault, Marie-Christine; Mancini, Francesca Romana; Mahamat-Saleh, Yahya; Aleksandrova, Krasimira; Kaaks, Rudolf; Kühn, Tilman; Trichopoulou, Antonia; Karakatsani, Anna; Panico, Salvatore; Tumino, Rosario; Palli, Domenico; Tagliabue, Giovanna; Naccarati, Alessio; Vermeulen, Roel C H; Bueno-de-Mesquita, Hendrik Bastiaan; Weiderpass, Elisabete; Skeie, Guri; Ramón Quirós, Jose; Ardanaz, Eva; Mokoroa, Olatz; Sala, Núria; Sánchez, Maria-Jose; Huerta, José María; Winkvist, Anna; Harlid, Sophia; Ohlsson, Bodil; Sjöberg, Klas; Schmidt, Julie A; Wareham, Nick; Khaw, Kay-Tee; Ferrari, Pietro; Rothwell, Joseph A; Gunter, Marc; Riboli, Elio; Scalbert, Augustin; Jenab, Mazda.
Afiliación
  • Stepien M; Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Keski-Rahkonen P; Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Kiss A; Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Robinot N; Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Duarte-Salles T; Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Murphy N; Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain.
  • Perlemuter G; Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Viallon V; INSERM UMRS U996 - Intestinal Microbiota, Macrophages and Liver Inflammation, Clamart, France.
  • Tjønneland A; Université Paris-Sud, Clamart, France.
  • Rostgaard-Hansen AL; AP-HP, Hepato-gastroenterology and Nutrition, Antoine-Béclère Hospital, Clamart, France.
  • Dahm CC; Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Overvad K; Diet, Genes and Environment Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Boutron-Ruault MC; Diet, Genes and Environment Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Mancini FR; Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark.
  • Mahamat-Saleh Y; Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark.
  • Aleksandrova K; Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
  • Kaaks R; CESP, Faculté de médecine-Université Paris-Sud, Faculté de médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Kühn T; Institut Gustave Roussy, Villejuif, France.
  • Trichopoulou A; CESP, Faculté de médecine-Université Paris-Sud, Faculté de médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Karakatsani A; Institut Gustave Roussy, Villejuif, France.
  • Panico S; CESP, Faculté de médecine-Université Paris-Sud, Faculté de médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Tumino R; Institut Gustave Roussy, Villejuif, France.
  • Palli D; Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany.
  • Tagliabue G; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Naccarati A; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Vermeulen RCH; Hellenic Health Foundation, Athens, Greece.
  • Bueno-de-Mesquita HB; WHO Collaborating Center for Nutrition and Health, Unit of Nutritional Epidemiology and Nutrition in Public Health, Dept. of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Weiderpass E; Hellenic Health Foundation, Athens, Greece.
  • Skeie G; Second Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Haidari, Greece.
  • Ramón Quirós J; Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
  • Ardanaz E; Cancer Registry and Histopathology Department, Provincial Health Authority (ASP) Ragusa, Ragusa, Italy.
  • Mokoroa O; Cancer Risk Factors and Life-Style Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy.
  • Sala N; Lombardy Cancer Registry Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Sánchez MJ; Molecular and Genetic Epidemiology Unit, Italian Institute for Genomic Medicine (IIGM) Torino, Torino, Italy.
  • Huerta JM; Institute of Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
  • Winkvist A; Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
  • Harlid S; Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands.
  • Ohlsson B; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Sjöberg K; Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Schmidt JA; Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Wareham N; Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
  • Khaw KT; Public Health Directorate, Asturias, Spain.
  • Ferrari P; Navarra Public Health Institute, Pamplona, Spain.
  • Rothwell JA; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
  • Gunter M; CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Riboli E; CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
  • Scalbert A; Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, Spain.
  • Jenab M; Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program and Translational Research Laboratory, Catalan Institute of Oncology (IDIBELL), Barcelona, Spain.
Int J Cancer ; 148(3): 609-625, 2021 02 01.
Article en En | MEDLINE | ID: mdl-32734650
ABSTRACT
Hepatocellular carcinoma (HCC) development entails changes in liver metabolism. Current knowledge on metabolic perturbations in HCC is derived mostly from case-control designs, with sparse information from prospective cohorts. Our objective was to apply comprehensive metabolite profiling to detect metabolites whose serum concentrations are associated with HCC development, using biological samples from within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (>520 000 participants), where we identified 129 HCC cases matched 11 to controls. We conducted high-resolution untargeted liquid chromatography-mass spectrometry-based metabolomics on serum samples collected at recruitment prior to cancer diagnosis. Multivariable conditional logistic regression was applied controlling for dietary habits, alcohol consumption, smoking, body size, hepatitis infection and liver dysfunction. Corrections for multiple comparisons were applied. Of 9206 molecular features detected, 220 discriminated HCC cases from controls. Detailed feature annotation revealed 92 metabolites associated with HCC risk, of which 14 were unambiguously identified using pure reference standards. Positive HCC-risk associations were observed for N1-acetylspermidine, isatin, p-hydroxyphenyllactic acid, tyrosine, sphingosine, l,l-cyclo(leucylprolyl), glycochenodeoxycholic acid, glycocholic acid and 7-methylguanine. Inverse risk associations were observed for retinol, dehydroepiandrosterone sulfate, glycerophosphocholine, γ-carboxyethyl hydroxychroman and creatine. Discernible differences for these metabolites were observed between cases and controls up to 10 years prior to diagnosis. Our observations highlight the diversity of metabolic perturbations involved in HCC development and replicate previous observations (metabolism of bile acids, amino acids and phospholipids) made in Asian and Scandinavian populations. These findings emphasize the role of metabolic pathways associated with steroid metabolism and immunity and specific dietary and environmental exposures in HCC development.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Carcinoma Hepatocelular / Metabolómica / Neoplasias Hepáticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Carcinoma Hepatocelular / Metabolómica / Neoplasias Hepáticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Francia